Summary
L0T Chart
GE Healthcare: Near-Term Margin Headwinds Priced In, Long-Term Growth Driven By New Products And M&As
GE Healthcare is well-positioned for growth, driven by a strong backlog, product innovation, and potential pent-up demand in China as stimulus funding is deployed. Margin headwinds from tariffs are expected to bottom in Q3, with management actively mitigating impacts through cost controls, local manufacturing, and pricing actions. Valuation is attractive versus peers, with current prices reflecting tariff risks and offering upside as margins recover and growth accelerates post-Q3.
GE HealthCare drives innovation in theranostics with latest technological advances
CHICAGO--(BUSINESS WIRE)--At this year's Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE HealthCare is spotlighting the future of precision care with its innovative portfolio of theranostics-enabling solutions designed to help drive clinical and operational excellence. Making its debut, GE HealthCare's MIM Software introduces LesionID Pro with automated zero-click pre-processingi – an AI-powered innovation to help aid physician decision making and therapy response m.
GE HealthCare Stock Slips Despite the Launch of bkActiv S Series
GEHC expands its bkPortfolio with the AI-powered bkActiv S Series to advance ultrasound-guided procedures.
GE Healthcare Technology Dividends
 GEHC In 1 month Estimated | Quarterly | $0.04 Per Share |
| GEHC 1 month ago Paid | Quarterly | $0.04 Per Share |
| GEHC 5 months ago Paid | Quarterly | $0.04 Per Share |
| GEHC 8 months ago Paid | Quarterly | $0.03 Per Share |
| GEHC 11 months ago Paid | Quarterly | $0.03 Per Share |
| GEHC 18 Apr 2024 Paid | Quarterly | $0.03 Per Share |
GE Healthcare Technology Earnings
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 13 Feb 2025 Date | | 1.26 Cons. EPS | 1.45 EPS |
| 30 Oct 2024 Date | | 1.05 Cons. EPS | 1.14 EPS |
| 31 Jul 2024 Date | | 0.98 Cons. EPS | 1 EPS |
| 30 Apr 2024 Date | | 0.91 Cons. EPS | 0.9 EPS |
| GEHC In 1 month Estimated | Quarterly | $0.04 Per Share |
| GEHC 1 month ago Paid | Quarterly | $0.04 Per Share |
| GEHC 5 months ago Paid | Quarterly | $0.04 Per Share |
| GEHC 8 months ago Paid | Quarterly | $0.03 Per Share |
| GEHC 11 months ago Paid | Quarterly | $0.03 Per Share |
| GEHC 18 Apr 2024 Paid | Quarterly | $0.03 Per Share |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 13 Feb 2025 Date | | 1.26 Cons. EPS | 1.45 EPS |
| 30 Oct 2024 Date | | 1.05 Cons. EPS | 1.14 EPS |
| 31 Jul 2024 Date | | 0.98 Cons. EPS | 1 EPS |
| 30 Apr 2024 Date | | 0.91 Cons. EPS | 0.9 EPS |
GE Healthcare Technology (L0T) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has GE Healthcare Technology ever had a stock split?
GE Healthcare Technology Profile
| Medical - Healthcare Information Services Industry | Healthcare Sector | Mr. Peter J. Arduini CEO | XMUN Exchange | US36266G1076 ISIN |
| US Country | 53,000 Employees | 25 Apr 2025 Last Dividend | - Last Split | 4 Jan 2023 IPO Date |
Overview
GE HealthCare Technologies Inc. is a globally recognized company deeply engaged in the healthcare sector, providing a wide range of products, services, and digital solutions aimed at improving patient care. With operations spread across the United States, Canada, and other international markets, the company commits itself to the development, manufacture, and marketing of innovative medical technologies. The organizational structure of GE HealthCare Technologies Inc. is divided into four primary segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics, each dedicated to addressing specific medical needs and advancing the field of medical diagnostics and patient care. Having evolved from GE Healthcare Holding LLC in December 2022, the company is now based in Chicago, Illinois, and continues to leverage its broad portfolio to facilitate the diagnosis, treatment, and monitoring of patients worldwide.
Products and Services
- Imaging
This segment provides a comprehensive range of imaging technologies such as molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. These advanced imaging solutions play a crucial role in diagnosing and managing various health conditions, enhancing the efficiency and effectiveness of medical treatments.
- Ultrasound
GE HealthCare Technologies Inc. offers a wide array of ultrasound devices and solutions designed for screening, diagnosis, treatment, and monitoring of diseases in numerous clinical areas. This includes radiology, primary care, women's health, cardiovascular, along with point of care and handheld ultrasound devices, and products for surgical visualization and guidance. Ultrasound technology facilitates non-invasive diagnostics and therapeutic procedures, making it an essential tool in modern healthcare.
- Patient Care Solutions
The company's offerings under this segment encompass a variety of medical devices, consumables, services, and digital solutions aimed at improving patient outcomes. The portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, and maternal infant care products, alongside a range of consumables and services. These solutions are integral to providing comprehensive care in various medical settings, from emergency rooms to intensive care units and beyond.
- Pharmaceutical Diagnostics
Specializing in diagnostic agents for radiology and nuclear medicine, this segment supplies essential products for CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound imaging. The products include contrast media pharmaceuticals that improve the visibility of tissues during diagnostic scans and molecular imaging agents or radiopharmaceuticals labeled with radioisotopes for detailed imaging studies. These diagnostic agents are pivotal in detecting and monitoring a wide range of diseases, aiding clinicians in formulating effective treatment plans.
Contact Information
